Alkermes Plc

Alkermes Plc Equity

The The Equity of Alkermes Plc (ALKS) as of Nov 19, 2026 is 1.46 B USD. In the previous year, The Equity was 1.20 B USD — a change of 21.81% (higher).

Equity

1.46 BUSD

YoY

21.81%

Last updated:

In 2024, Alkermes Plc's equity was 1.46 B USD, a 21.81% increase from the 1.20 B USD equity in the previous year.

The Alkermes Plc Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
1.20 B USD
Jan 1, 2018
1.17 B USD
Jan 1, 2019
1.09 B USD
Jan 1, 2020
1.07 B USD
Jan 1, 2021
1.11 B USD
Jan 1, 2022
1.04 B USD
Jan 1, 2023
1.20 B USD
Jan 1, 2024
1.46 B USD
The Alkermes Plc Equity history
YEAREquityYoY
1.46 BUSD+21.81%
1.20 BUSD+15.22%
1.04 BUSD-6.18%
1.11 BUSD+4.27%
1.07 BUSD-1.70%
1.09 BUSD-7.33%
1.17 BUSD-2.62%
1.20 BUSD-0.55%
1.21 BUSD-7.97%
1.31 BUSD-5.91%
1.40 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alkermes Plc Stock analysis

What does Alkermes Plc do? Alkermes Plc is a leading biopharmaceutical company specializing in the development of innovative drugs for serious diseases since its establishment in 1987. The company is headquartered in Dublin, Ireland, and employs over 2,000 people worldwide. Alkermes Plc is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Alkermes Plc's Equity

Alkermes Plc's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Alkermes Plc's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Alkermes Plc's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Alkermes Plc's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Alkermes Plc’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Alkermes Plc stock

The Equity of Alkermes Plc is 1.46 B USD in 2024.

The Equity of Alkermes Plc changed from 1.20 B USD to 1.46 B USD, representing a 21.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Alkermes Plc since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Alkermes Plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alkermes Plc

All Key Metrics — Alkermes Plc